Silence Therapeutics (SLN)
NASDAQ:SLN
Want to see SLN full AI Analyst Report?
SLN Stock Chart & Stats
$7.53
-$0.25(-3.72%)
At close: 4:00 PM EST
$7.53
-$0.25(-3.72%)
Day’s Range― - ―
52-Week Range$4.19 - $8.40
Previous CloseN/A
Volume50.54K
Average Volume (3M)101.05K
Market Cap
$300.88M
Enterprise Value$320.39M
Total Cash (Recent Filing)$70.08M
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.32
Shares Outstanding47,234,610
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue347.69
Enterprise Value/Gross Profit523.42
Enterprise Value/Ebitda-4.06
Forecast
1Y Price Target
$27.59Price Target Upside266.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$4.16M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMinimal financial leverage is a durable strength for a development-stage biotech: it reduces liquidity stress from interest obligations, preserves flexibility to fund R&D or partner deals, and lowers near-term default risk, extending runway compared with highly leveraged peers.
High Gross MarginsSustained high gross margins imply the company's platform/partnered revenue is economically attractive. That structural margin profile supports long-term scalability for licensing or product sales, enabling better absorption of fixed R&D costs once revenue scales.
Pipeline Progress & PartneringAdvancing SANRECO faster and positioning zerlasiran for partnership materially improves strategic optionality: clearer clinical timelines reduce program uncertainty and partnerability can de-risk capital needs, accelerate commercialization paths and create milestone/royalty revenue streams.
Bears Say
Persistent Cash BurnContinued negative operating and free cash flow is a durable pressure: it forces recurrent capital raises or partner financing, diluting shareholders and creating execution risk if funding terms worsen, while limiting the firm's ability to self-fund multiple late-stage programs simultaneously.
Large Net Losses & Declining EquitySteep net losses that materially erode equity indicate the company is consuming shareholder capital faster than it generates partner income. That structural deficit reduces strategic flexibility, pressures the balance sheet over multiple quarters, and raises the probability of dilutive funding events.
Partner Setback & Leadership TransitionLoss of a development partner removes external development resources and potential milestone revenue, increasing internal funding needs. Coupled with an interim CEO appointment, this raises medium-term execution risk for complex trials and partnering negotiations until leadership and partner strategies stabilize.
Silence Therapeutics News
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $4.19 and its highest was $8.40 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $300.88M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on May 07, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.129 by $0.019.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 47,234,610 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.129. Following the earnings report the stock price went down -5.571%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.59 (266.40% Upside)
$27.59 (266.40% Upside)
Hedge Fund Trend
Decreased
By 70.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-64.86%
12-Months-Change
Fundamentals
Return on Equity
-107.19%
Trailing 12-Months
Asset Growth
-37.87%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
SLN Stock 12 Month Forecast
Average Price Target
$27.59
▲(266.40% Upside)
Technical Analysis
Ownership Overview
22.15%
Insiders
0.10% Mutual Funds
32.00% Other Institutional Investors
45.20% Public Companies and
Individual Investors